Astellas Sees Turnaround With Urology, Transplantation And Oncology Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresh off a long-fought bid for OSI, Astellas has rolled out a five-year management plan to bounce back from patent expires and declining sales.
You may also be interested in...
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17, 2010 with a definitive merger agreement that has the unanimous support of both companies' boards. The victory cost $4 billion, about $500 million more than the original hostile bid which Astellas launched in late February ("The Pink Sheet" DAILY, March 1, 2010)
Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth
Astellas Sees Clouds Over Prograf, Irribow; Launches Vesicare In Asia To Drive Growth
Facing U.S. market expansion for generic Prograf (tacrolimus), a 14-year running blockbuster immunosuppressant, Japan's second-largest drug maker Astellas hopes to cultivate its next blockbuster from mirabegron, and ride the strong performance of Vesicare (solifenacin) to drive global growth by launching the drug in emerging Asian markets such as Singapore and China